There are currently 196 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
NCT05434689
Recruiting
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administrat... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
02/28/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +5 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354
Recruiting
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +16 locations
Conditions: Multiple Myeloma
Register for Updates
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04126200
Recruiting
B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single m... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: GSK Investigational Site, Atlanta, Georgia +58 locations
Conditions: Multiple Myeloma
Register for Updates
Family Study of Lymphoproliferative Disorders
NCT00626496
Recruiting
Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic leukemia and non-Hodgkin lymphoma. Since there is evidence that these cancers cluster in families, this study aims to understand how genetics and environmental exposures contribute to the development o... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
02/23/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Monoclonal B-Cell Lymphocytosis, Multiple Myeloma
Register for Updates
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
NCT05027594
Recruiting
This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida +5 locations
Conditions: Multiple Myeloma
Register for Updates
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
NCT05393804
Recruiting
The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/19/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Multiple Myeloma
Register for Updates
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
NCT05556928
Recruiting
The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.
Gender:
All
Ages:
50 years and above
Trial Updated:
02/19/2024
Locations: Kirklin Clinic of UAB Hospital, Birmingham, Alabama
Conditions: Multiple Myeloma, Amyloidosis, Plasma Cell Leukemia
Register for Updates
Fluoroquinolone Resistance Prevalence Study
NCT05824689
Recruiting
This is an exploratory study to determine the prevalence of fluoroquinolone resistance in patients receiving dose-intense melphalan with autologous peripheral blood stem cell (PBSC) transplantation in the treatment of multiple myeloma (MM). These data may be used in subsequent studies exploring the use of prophylaxis in this patient population.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia +1 locations
Conditions: Multiple Myeloma
Register for Updates
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881
Recruiting
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mort... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
02/15/2024
Locations: City of Hope, Duarte, California +14 locations
Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Register for Updates
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
NCT05271630
Recruiting
The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma
NCT06073353
Recruiting
This clinical trial aims to evaluate whether a psychosocial mobile application (THRIVE-M), is efficacious for improving quality of life, psychological distress, and fatigue in patients living with multiple myeloma compared to usual care.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT04354246
Recruiting
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/10/2024
Locations: Florida Cancer Specialists, Sarasota, Florida +8 locations
Conditions: Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Register for Updates